1. Home
  2. |Insights
  3. |CBI’s Premiere Forum on Bio/Pharmaceutical and Medical Device Corporate Integrity Agreements (CIAs)

CBI’s Premiere Forum on Bio/Pharmaceutical and Medical Device Corporate Integrity Agreements (CIAs)

Event | 06.17.09 - 06.18.09, 12:00 AM UTC - 12:00 AM UTC

When manufacturers settle with the government for alleged wrongdoing – many times focused on fraudulent promotion or kickback allegations – in addition to hefty fines, the organization enters into a Corporate Integrity Agreement (CIA) with the OIG. While each agreement differs by focusing specifically on each manufacturer’s conduct issues, these agreements are an invaluable asset to compliance teams as they give insight into the government’s expectations and standards for various compliance challenges.

In this forum, hear best practices that have been developed following an integrity obligation. Attendees come from both companies currently operating under a CIA and those that are not. Session leaders explain how they improved or changed their processes and how these enhancements can be applied at any company to develop an overall more efficient and effective compliance program.

Karen Gibbs is one of the speakers at this event. The topic is "Refine Policies and Procedures and Implement through Effective and Efficient Training Programs". She is addressing the 'Implement Effective and Efficient Training Programs' portion.

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.